| 袁璟智,尚桂莲,周文煜,熊 静,刘 柳.基于炎症免疫调节探讨艾拉莫德联合硫酸羟氯喹治疗类风湿关节炎的疗效及作用机制[J].现代生物医学进展英文版,2024,(9):1712-1716. |
| 基于炎症免疫调节探讨艾拉莫德联合硫酸羟氯喹治疗类风湿关节炎的疗效及作用机制 |
| Exploring the Therapeutic Effectiveness and Mechanism of the Combination of Alamod and Hydroxychloroquine Sulfate in the Treatment of Rheumatoid Arthritis Based on Inflammatory Immune Regulation |
| Received:November 12, 2023 Revised:December 10, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.09.022 |
| 中文关键词: 炎症反应 免疫反应 艾拉莫德 硫酸羟氯喹 类风湿关节炎 疗效 作用机制 |
| 英文关键词: Inflammatory response Immune response Alamod Hydroxychloroquinone sulfate Rheumatoid arthritis Therapeutic effectiveness Mechanism |
| 基金项目:湖北省自然科学基金项目（2020CFB595）；武汉市卫生和计划生育委员会科研项目 （WZ18Q13） |
|
| Hits: 338 |
| Download times: 176 |
| 中文摘要: |
| 摘要 目的：基于炎症免疫调节探讨艾拉莫德联合硫酸羟氯喹治疗类风湿关节炎（RA）的疗效及作用机制。方法：选择2021年4月~2023年3月期间武汉科技大学附属天佑医院和武汉市第四医院收治的120例RA患者。根据随机数字表法将患者分为对照组和研究组，每组各为60例。对照组接受硫酸羟氯喹治疗，研究组接受艾拉莫德联合硫酸羟氯喹治疗。对比两组疗效、临床症状缓解时间、炎症因子[肿瘤坏死因子α（TNF-α）、白细胞介素-6（IL-6）、干扰素α（IFN-α）、干扰素-γ（IFN-γ）]、视觉疼痛模拟评分（VAS）和简易健康生活质量评分（SF-36）、免疫因子[T淋巴细胞亚群（CD4+、CD8+、CD4+/CD8+）、免疫球蛋白（Ig）G、IgM、IgA]。同时观察两组用药安全性。结果：与对照组相比，研究组的临床总有效率更高（P<0.05）。研究组的关节疼痛、关节肿胀、关节晨僵缓解时间均短于对照组（P<0.05）。治疗6个月后，两组TNF-α、IL-6、IFN-γ、IFN-α下降，且研究组低于对照组（P<0.05）。治疗6个月后，两组CD8+升高，且研究组高于对照组；CD4+、CD4+/CD8+降低，且研究组低于对照组（P<0.05）。治疗6个月后，两组IgG、IgM、IgA下降，且研究组低于对照组（P<0.05）。治疗6个月后，两组VAS评分下降，且研究组低于对照组；SF-36评分升高，且研究组高于对照组（P<0.05）。两组不良反应发生率组间对比未见差异（P>0.05）。结论：艾拉莫德联合硫酸羟氯喹治疗RA，疗效确切，能缩短临床症状缓解时间，缓解关节疼痛和提高患者生活质量，且用药安全、副作用少，其作用机制可能与调节炎症反应、免疫反应有关。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the therapeutic effectiveness and mechanism of the combination of alamod and hydroxychloroquine sulfate in the treatment of rheumatoid arthritis (RA) based on inflammatory immune regulation. Methods: A total of 120 RA patients were admitted to the Tianyou Hospital Affiliated to Wuhan University of Science and Technology and Wuhan Fourth Hospital from April 2021 to March 2023. According to the random number table method, patients were divided into a control group and a study group, with 60 cases in each group. The control group patients received hydroxychloroquine sulfate treatment, while the study group patients received combination therapy with alamod and hydroxychloroquine sulfate.Compared the therapeutic effectiveness, clinical symptom relief time, and inflammatory factors [tumor necrosis factor α (TNF-α)], Interleukin-6 (IL-6), interferon α (IFN- α), Interferon- γ (IFN-γ)], Visual Pain Simulation Scale (VAS) and Simplified Healthy Quality of Life (SF-36), immune function factors [T lymphocyte subpopulations (CD4+, CD8+, CD4+/CD8+), immunoglobulins (Ig) G, M, A] between two groups. Simultaneously observed the safety of medication in both groups. Results: Compared with the control group, the clinical total effective rate of the study group was higher (P<0.05). The relief time of arthralgia, arthroncus, morning stiffness of joint in study group were shorter than those in control group (P<0.05). After 6 months of treatment, both groups of TNF-α, IL-6, IFN-γ, IFN-α decreased, and the study group was lower than the control group (P<0.05). After 6 months of treatment, CD8+ increased in both groups, and the study group was higher than the control group; CD4+ and CD4+/CD8+ decreased, and the study group was lower than the control group(P<0.05). After 6 months of treatment, IgG, IgM, and IgA decreased in both groups, and the study group was lower than the control group (P<0.05). After 6 months of treatment, the VAS scores of both groups decreased, and the study group was lower than the control group; The SF-36 score increased, and the study group was higher than the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of Alamod and hydroxychloroquine sulfate in the treatment of RA has a definite therapeutic effectiveness, which can shorten the symptom relief time, relieve joint pain and improve the quality of life of patients, and the medication is safe with few side effects. The mechanism of action may be related to the regulation of inflammatory response and immune response. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
